: ATP13A2 is a gene localized on chromosome 1p36.13 and coding for a transmembrane protein found in the lysosomes and late endosomes, which is involved in many cellular metabolic activities. Pathogenetic variants of ATP13A2 are associated with a wide range of neurodegenerative disorder including Kufor Rakeb syndrome (KRS), a rare autosomal recessive form of levodopa responsive juvenile onset parkinsonism (MxMD-ATP13A2), characterized by rapidly progressive muscular stiffness, bradykinesia, spasticity, pyramidal findings, dementia and supranuclear gaze palsy. The aim of this study is to provide detailed clinical descriptions of two siblings, carriers of novel biallelic ATP13A2 variants. One of them showed KRS levodopa-responsive motor dystonic features at the age of 10 years preceded by moderate cognitive impairment, while the other only showed mild cognitive impairment at our last evaluation at 11 years of age. Additionally, we reviewed the previously published cases, focusing on early signs and symptoms, clinical evolution and response to therapy. To our knowledge, this is the only work that groups all reported KRS patients and compares their clinical and molecular features.

Affronte, L., Pini, A., Pizzoli, C., Coccia, E., Mazzone, S., Golemi, A., et al. (2025). Case Report: Novel ATP13A2 pathogenic variants associated with early-onset parkinsonism and a mini-review. FRONTIERS IN GENETICS, 16, 1-12 [10.3389/fgene.2025.1588812].

Case Report: Novel ATP13A2 pathogenic variants associated with early-onset parkinsonism and a mini-review

Affronte, Leonardo;Coccia, Emanuele;Mazzone, Serena;Cordelli, Duccio Maria;Carelli, Valerio;Vaisfeld, Alessandro;
2025

Abstract

: ATP13A2 is a gene localized on chromosome 1p36.13 and coding for a transmembrane protein found in the lysosomes and late endosomes, which is involved in many cellular metabolic activities. Pathogenetic variants of ATP13A2 are associated with a wide range of neurodegenerative disorder including Kufor Rakeb syndrome (KRS), a rare autosomal recessive form of levodopa responsive juvenile onset parkinsonism (MxMD-ATP13A2), characterized by rapidly progressive muscular stiffness, bradykinesia, spasticity, pyramidal findings, dementia and supranuclear gaze palsy. The aim of this study is to provide detailed clinical descriptions of two siblings, carriers of novel biallelic ATP13A2 variants. One of them showed KRS levodopa-responsive motor dystonic features at the age of 10 years preceded by moderate cognitive impairment, while the other only showed mild cognitive impairment at our last evaluation at 11 years of age. Additionally, we reviewed the previously published cases, focusing on early signs and symptoms, clinical evolution and response to therapy. To our knowledge, this is the only work that groups all reported KRS patients and compares their clinical and molecular features.
2025
Affronte, L., Pini, A., Pizzoli, C., Coccia, E., Mazzone, S., Golemi, A., et al. (2025). Case Report: Novel ATP13A2 pathogenic variants associated with early-onset parkinsonism and a mini-review. FRONTIERS IN GENETICS, 16, 1-12 [10.3389/fgene.2025.1588812].
Affronte, Leonardo; Pini, Antonella; Pizzoli, Claudia; Coccia, Emanuele; Mazzone, Serena; Golemi, Arber; Giannotta, Melania; Cordelli, Duccio Maria; C...espandi
File in questo prodotto:
File Dimensione Formato  
Novel ATP13A2_Front genetics_2025.pdf

accesso aperto

Descrizione: articolo
Tipo: Versione (PDF) editoriale / Version Of Record
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 750.5 kB
Formato Adobe PDF
750.5 kB Adobe PDF Visualizza/Apri
Table 1.docx

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 19.61 kB
Formato Microsoft Word XML
19.61 kB Microsoft Word XML Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1035670
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact